The biotech has built a “comprehensive and complementary” platform that combines its proprietary delivery technologies, including novel lipid nanoparticles (LNPs), with a broad array of coding, editing, and gene insertion tools, in an all-RNA system.
ReNAgade aims to address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body, substantially expanding the potential addressable disease market.
In addition, the company has an established joint venture with Orna Therapeutics, combining its delivery platform with Orna’s circular RNA technology. Subsequently, Orna has entered into a collaboration with Merck, which includes technologies developed under the Orna/ReNAgade JV.
"ReNAgade was founded on a bold idea – to dramatically transcend the boundaries of RNA medicine, a field that has made great strides but remains in its infancy," said Ansbert Gadicke, managing partner of MPM Bioimpact and founder of ReNAgade.
"By innovating on delivery technology and bringing an array of genomic medicine tools under one roof, ReNAgade is poised to deliver RNA to organs and tissues not previously accessible. ReNAgade’s joint venture with Orna provides early validation of the technologies that ReNAgade will continue to bring forward."
Amit Munshi, CEO of ReNAgade, added: “In order to fulfill our mission to develop RNA medicines with the potential to treat any disease anywhere in the body, we have curated a world-class, multidisciplinary team who have collectively achieved 25 NDAs, including four in RNA medicines, and 200 INDs, and have been pioneers in the field of RNA medicines.”
"We are further buoyed by the support of our long-term investors and validated by the progress we have made to date—making us well-positioned to expand the reach of RNA medicine far beyond what was previously thought possible."
